Stifel analyst Rick Wise initiated coverage of Heartflow (HTFL) with a Buy rating and $35 price target The firm believes the company’s FFR CT and Plaque Analysis technology offers “meaningful value” for every coronary artery disease stakeholder. The company’s plaque analysis technology reimbursement in January should drive growth and potentially position plaque analysis software as an incremental growth driver for 2026 and beyond, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HTFL:
- Heartflow initiated with an Overweight at JPMorgan
- Heartflow initiated with an Overweight at Piper Sandler
- HeartFlow, Inc.: Innovative Technology and Strong Financial Performance Drive Buy Rating
- HeartFlow, Inc.: Positioned for Growth in AI-Powered Coronary Diagnostics with Strong Market Potential
- Innovative AI-Driven Diagnostics Propel HeartFlow, Inc. to Buy Rating